Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models
- 25 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 20 (5), 915-924
- https://doi.org/10.1158/1535-7163.mct-20-0228
Abstract
Effective treatments for patients with mCRPC following disease progression on enzalutamide is currently an unmet clinical need. Simultaneous inhibition of HIF-1α and AR pathways has been previously shown to overcome enzalutamide resistance in vitro. Combination treatment with NLG207, a nanoparticle-drug conjugate of camptothecin and inhibitor of HIF-1α, and enzalutamide was evaluated in preclinical prostate cancer models of enzalutamide resistance. The effect of NLG207 and enzalutamide on average tumor volume and tumor re-growth after 3 weeks of treatment was evaluated in vivo using the subcutaneous 22Rv1 xenograft and castrated subcutaneous VCaP xenograft models. Correlative assessments of anti-tumor activity were evaluated in vitro using cell proliferation and qPCR assays. NLG207 8 mg/kg alone and in combination with enzalutamide reduced average tumor volume by 93% after 3 weeks of treatment (p<0.05) in comparison to vehicle control in the subcutaneous 22Rv1 xenograft model. Notably, the addition of NLG207 also enhanced the efficacy of enzalutamide alone in the castrated subcutaneous VCaP xenograft model, decreasing the median rate of tumor growth by 51% (p=0.0001) in comparison to enzalutamide alone. In vitro assessments of cell proliferation and gene expression further demonstrated anti-tumor activity via AR-HIF-1α crosstalk inhibition. Combination treatment with NLG207 and enzalutamide was shown to be effective in preclinical prostate cancer models of enzalutamide resistance. Clinical investigation of this treatment combination is ongoing (NCT03531827).Keywords
Other Versions
Funding Information
- Intramural Research Program of the Center for Cancer Research National Cancer Institute National Institutes of Health (ZIA BC 010547)
This publication has 59 references indexed in Scilit:
- The updated biology of hypoxia-inducible factorThe EMBO Journal, 2012
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1Cancer Cell, 2011
- Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer ProgressionCancer Research, 2011
- Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growthBiochemical and Biophysical Research Communications, 2010
- The relevance of a hypoxic tumour microenvironment in prostate cancerBJU International, 2009
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsOncogene, 2009
- Reactivation of Androgen Receptor–Regulated TMPRSS2:ERG Gene Expression in Castration-Resistant Prostate CancerCancer Research, 2009
- Androgen‐insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen‐dependent prostate environmentThe Prostate, 2006
- Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer ModelsClinical Cancer Research, 2006
- Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma XenograftsCancer Research, 2004